Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Child Abuse | 2 | 2021 | 193 | 0.790 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2021 | 36 | 0.770 |
Why?
|
| Rib Fractures | 1 | 2020 | 30 | 0.770 |
Why?
|
| Appendicitis | 2 | 2021 | 169 | 0.750 |
Why?
|
| Surgical Stapling | 1 | 2011 | 36 | 0.390 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2017 | 427 | 0.340 |
Why?
|
| Anastomosis, Surgical | 1 | 2011 | 371 | 0.340 |
Why?
|
| Palivizumab | 4 | 2017 | 64 | 0.330 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 275 | 0.320 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2008 | 121 | 0.320 |
Why?
|
| Biocompatible Materials | 1 | 2008 | 202 | 0.310 |
Why?
|
| Intestines | 1 | 2011 | 686 | 0.280 |
Why?
|
| Antiviral Agents | 4 | 2017 | 1230 | 0.270 |
Why?
|
| Collagen | 1 | 2008 | 752 | 0.260 |
Why?
|
| Aneurysm, Ruptured | 2 | 2014 | 45 | 0.240 |
Why?
|
| Intracranial Aneurysm | 2 | 2014 | 123 | 0.230 |
Why?
|
| Medical Overuse | 1 | 2021 | 45 | 0.200 |
Why?
|
| Physical Abuse | 1 | 2021 | 23 | 0.200 |
Why?
|
| Trauma Centers | 1 | 2021 | 163 | 0.190 |
Why?
|
| Patient Transfer | 1 | 2021 | 137 | 0.190 |
Why?
|
| Leg | 1 | 2021 | 226 | 0.180 |
Why?
|
| Thigh | 1 | 2021 | 172 | 0.180 |
Why?
|
| Brain Concussion | 1 | 2021 | 194 | 0.170 |
Why?
|
| Infant | 7 | 2021 | 13310 | 0.170 |
Why?
|
| Abdominal Pain | 1 | 2021 | 369 | 0.160 |
Why?
|
| Wounds and Injuries | 1 | 2021 | 399 | 0.150 |
Why?
|
| Child, Preschool | 6 | 2021 | 16273 | 0.150 |
Why?
|
| Angiotensin I | 1 | 2014 | 18 | 0.120 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 142 | 0.120 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2017 | 211 | 0.120 |
Why?
|
| Phlebotomy | 1 | 2014 | 26 | 0.120 |
Why?
|
| Colon, Sigmoid | 1 | 2013 | 42 | 0.110 |
Why?
|
| Algorithms | 2 | 2021 | 3890 | 0.110 |
Why?
|
| Critical Pathways | 1 | 2014 | 149 | 0.110 |
Why?
|
| Colonic Diseases | 1 | 2013 | 71 | 0.110 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2014 | 176 | 0.110 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2010 | 171 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2016 | 492 | 0.100 |
Why?
|
| Spleen | 1 | 2014 | 676 | 0.100 |
Why?
|
| Respiratory Sounds | 2 | 2010 | 95 | 0.100 |
Why?
|
| Vagina | 1 | 2013 | 317 | 0.100 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 268 | 0.090 |
Why?
|
| Infant, Newborn | 5 | 2021 | 8223 | 0.090 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 310 | 0.090 |
Why?
|
| Appendectomy | 1 | 2010 | 124 | 0.090 |
Why?
|
| Suture Techniques | 1 | 2011 | 319 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2014 | 1271 | 0.080 |
Why?
|
| Polytetrafluoroethylene | 1 | 2008 | 113 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2013 | 5542 | 0.080 |
Why?
|
| Child | 5 | 2021 | 29154 | 0.080 |
Why?
|
| Injury Severity Score | 2 | 2021 | 237 | 0.080 |
Why?
|
| Adolescent | 5 | 2021 | 31252 | 0.080 |
Why?
|
| Humans | 15 | 2021 | 261506 | 0.070 |
Why?
|
| Prostheses and Implants | 1 | 2008 | 295 | 0.070 |
Why?
|
| Respiratory Tract Infections | 1 | 2010 | 437 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 4367 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2020 | 37905 | 0.070 |
Why?
|
| Canada | 2 | 2017 | 429 | 0.070 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2008 | 324 | 0.060 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2021 | 441 | 0.060 |
Why?
|
| Age Factors | 2 | 2011 | 5377 | 0.060 |
Why?
|
| Liver | 1 | 2014 | 2961 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2016 | 32848 | 0.060 |
Why?
|
| Female | 9 | 2021 | 141928 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2008 | 581 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 998 | 0.050 |
Why?
|
| Asthma | 1 | 2010 | 871 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2007 | 787 | 0.050 |
Why?
|
| Ambulances | 1 | 2021 | 24 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2010 | 1225 | 0.050 |
Why?
|
| Hospitalization | 3 | 2017 | 2083 | 0.050 |
Why?
|
| Emergency Treatment | 1 | 2021 | 105 | 0.050 |
Why?
|
| Recurrence | 1 | 2008 | 4758 | 0.050 |
Why?
|
| Triage | 1 | 2021 | 252 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 524 | 0.040 |
Why?
|
| Aged | 2 | 2020 | 70117 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2008 | 1697 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 661 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 429 | 0.040 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2021 | 367 | 0.040 |
Why?
|
| Italy | 1 | 2017 | 236 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2021 | 674 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 770 | 0.030 |
Why?
|
| Length of Stay | 2 | 2014 | 1900 | 0.030 |
Why?
|
| E-Selectin | 1 | 2014 | 103 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2021 | 1335 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 121 | 0.030 |
Why?
|
| Male | 7 | 2016 | 123000 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1148 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2021 | 6869 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2017 | 12873 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2014 | 330 | 0.030 |
Why?
|
| Pyrazines | 1 | 2014 | 495 | 0.030 |
Why?
|
| Animals | 3 | 2014 | 59536 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 419 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 488 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2014 | 583 | 0.020 |
Why?
|
| Triazoles | 1 | 2014 | 617 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 891 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2010 | 14889 | 0.020 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2013 | 356 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2014 | 548 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 636 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 1467 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 4988 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 1129 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2010 | 3251 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 538 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 12926 | 0.020 |
Why?
|
| Food Hypersensitivity | 1 | 2010 | 135 | 0.020 |
Why?
|
| Risk Factors | 2 | 2017 | 17523 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 5637 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 866 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2007 | 329 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2010 | 773 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 1099 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 2488 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 2292 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 5710 | 0.020 |
Why?
|
| United States | 1 | 2021 | 15433 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 6942 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 2403 | 0.010 |
Why?
|
| Mice | 2 | 2014 | 34495 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 7222 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 2588 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 3472 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 3441 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 4298 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 4938 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 11965 | 0.010 |
Why?
|
| Adult | 1 | 2014 | 77950 | 0.010 |
Why?
|
| Middle Aged | 1 | 2014 | 86204 | 0.000 |
Why?
|